New hope against Drug-Resistant fungal infections?
NCT ID NCT03604705
First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 31 times
Summary
This study tested a new antifungal drug called APX001 in 21 adults with a serious bloodstream fungal infection (candidemia), including cases where standard treatments might not work. Participants received the drug for up to 14 days, with possible extra treatment afterward. The goal was to see if the infection cleared and if the drug was safe.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CANDIDEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Augusta University (Georgia Regents University)
Augusta, Georgia, 30901, United States
-
CHU de Charleroi - Hopital Civil Marie Curie
Lodelinsart, Belgium
-
Duke University Hospital Medical Center
Durham, North Carolina, 27710, United States
-
Hopital Erasme
Brussels, 1070, Belgium
-
Hospital General Universitario de Alicante
Alicante, Spain
-
Hospital Universitari Vall d'Hebron
Barcelona, 08035, Spain
-
Hospital Universitario Mutua de Terrassa
Terrassa, Barcelona, Spain
-
Hospital VLL D Hebron
Barcelona, Spain
-
Infectious Diseases Unit
Tel Aviv, 6423906, Israel
-
Infectious Diseases Unit, Rambam Medical Center
Haifa, 3109601, Israel
-
Infectious Diseases Unit,Sheba Medical Center
Tel Litwinsky, 52621, Israel
-
Institut Jules Bordet
Brussels, Belgium
-
Institut Jules Bordet,Service De Microbiologie
Brussels, 1000, Belgium
-
Klinik I fur Innere Medizin- Uniklinik Koln
Cologne, Germany
-
Mont-Godinne University Hospital
Yvoir, 5530, Belgium
-
Rambam Medical Center
Haifa, Israel
-
Sheba Medical Center
Tel Litwinsky, Israel
-
Sourasky Medical Center
Tel Aviv, Israel
-
Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz - III. Medizinische Klinik Haematologie/Onkologie
Mainz, Germany
-
Universite Libre de Bruxelles (ULB) - Hopital Erasme
Brussels, Belgium
-
University Hospital Heidelberg
Heidelberg, Germany
-
University Hospital Mont-Godinne
Yvoir, Belgium
-
University of Alabama at Birmingham (UAB)
Birmingham, Alabama, 35249, United States
-
University of Alabama at Birmingham School of Medicine
Birmingham, Alabama, 35233, United States
-
University of California, Davis
Davis, California, 95616, United States
-
University of California-Davis Medical Center
Sacramento, California, 95817, United States
-
University of Chicago
Chicago, Illinois, 60637, United States
-
University of Texas- Health Science Center and Medical School at Houston
Houston, Texas, 77030, United States
-
Washington University
St Louis, Missouri, 63110, United States
Conditions
Explore the condition pages connected to this study.